Regeneron Pharmaceuticals Inc (REGN.OQ)
22 Jun 2018
Thu, May 3 2018
* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)
* REGENERON REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS
May 3 Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.
Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS
May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.
May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma
* FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
* REGENERON PHARMACEUTICALS INC SAYS PRESIDENT AND CEO LEONARD S. SCHLEIFER'S 2017 TOTAL COMPENSATION WAS $26.5 MILLION VERSUS $28.3 MILLION IN 2016 – SEC FILING
PARIS The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.
- 3 Things In Biotech, June 23: Regeneron Spiders Out With Inovio, Synairgen Proving Astra Wrong?
- Venture Capital Deals Of The Week: Tencent Bets On Online Education
- What Does Breakthrough Therapy Designation Really Mean For My Company?
- 3 Things In Biotech, June 21: Regeneron Sneaks Up In The Kidney Cancer Space
- Sell Kraft-Heinz At $64-65 - Cramer's Lightning Round (6/21/18)
- Brief Mid-Year Update On 2018 Global Asset Allocation